MedTrace Logo

Efficacy of Atorvastatin in Chronic Subdural Haematoma

NCT03956368 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 690

Last updated 2021-11-22

No results posted yet for this study

Summary

This prospective, double-blind, randomized, placebo-controlled study aims to evaluate the efficacy and safety of atorvastatin in patients with chronic subdural haematoma. The degree of disability or dependence in daily activities, as well as surgical intervention or recurrence, of the treatment and control groups will be compared.

Conditions

  • Chronic Subdural Hematoma

Interventions

DRUG

Atorvastatin 20mg

20mg (every evening orally) for 8 weeks.

DRUG

Placebos

20mg (every evening orally) for 8 weeks.

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Wai Sang Poon, MBChB-Glasg FRCSEd FHKAM-Surg · Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-09
Primary Completion
2022-09-16
Completion
2023-03-16

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03956368 on ClinicalTrials.gov